August 30, 2014 7:28 AM ET

Pharmaceuticals

Company Overview of Cadila Pharmaceuticals Limited

Company Overview

Cadila Pharmaceuticals Limited operates as a pharmaceutical company worldwide. The company develops branded and generic formulations for humans and animals; active pharmaceutical ingredients; biotechnology products and diagnostic kits; and plant tissue cultures. It also offers contract research and contract manufacturing services. The company offers its products for various therapeutic areas, including cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives, antibiotics, respiratory, anti diabetics, immunologicals, antipyretics, anthelmintics, anti-hypertensives, anti-inflammatory preparations, antibacterials, vitamins, iron and protein tonics, and ophthalmology. It has a ...

Sarkhej-Dholka Road

Bhat

Ahmedabad,  382210

India

Phone:

91 27 1822 5001

Fax:

91 27 1822 5039

Key Executives for Cadila Pharmaceuticals Limited

Chairman and Managing Director
Age: 54
Company Secretary
Compensation as of Fiscal Year 2014.

Cadila Pharmaceuticals Limited Key Developments

NovaSAID AB Announces Strategic Partnership with Cadila Pharmaceuticals Limited to Develop Innovative Treatments in Inflammation and Pain Management

NovaSAID AB and Cadila Pharmaceuticals Ltd. announced a strategic partnership to develop new treatments for inflammation and pain in conditions such as rheumatoid arthritis. The companies will collaborate around preclinical and clinical development of drug candidates that have been developed by NovaSAID and the development will be onducted at Cadila Pharmaceuticals’ facility in Ahmedabad, India. According to the agreement, all revenue generated from the sale and marketing in India, Middle East and Africa of products covered by the agreement will be retained by Cadila and net sales in all other countries will be shared by the two companies. Cadila will bear all costs associated with the program through to Phase II. Many of the medical treatments for inflammation and pain are associated with unwanted side effects such as an increased risk for myocardial infarction and gastric ulcers. NovaSAID’s drug candidates targets an enzyme called microsomal prostaglandin E synthase -1 (mPGES-1), a critically important mediator of inflammation and pain, which theoretically should reduce the risk for side effects. The collaboration with Cadila will provide the resources to take this program into clinical development and further towards the market.

Cadila Pharma to Launch Low-Cost Lung Cancer Drug in India

Cadila Pharmaceuticals plans to launch an innovative drug for the treatment of non-small-cell lung cancer (NSCLC) in the Indian market by December 2014. The drug, which will be marketed under the brand name Mycidac-C, targets desmocolin-3 protein. The drug will reportedly be sold at a 'low cost' - a course of 10 injections being priced at INR 40,000.

Helperby and Cadila Pharmaceuticals Announces Research Partnership and Licensing Agreement for Development of Products to Tackle Antibiotic Resistance

Helperby and Cadila Pharmaceuticals have announced a research partnership and licensing agreement aimed at the development of products to tackle antibiotic resistance. The deal involves Cadila licensing Helperby's HT61, a candidate antibiotic resistance breaker, from clinical trial stages to regulatory approval and commercialisation. Cadila will also be responsible for combining HT61 with existing antibiotics. A copy of the Helperby press release can be accessed here. The partnership is likely to leverage Cadila's experience in clinical development and regulatory approval. ARBs offer a potential weapon against antibiotic resistance and are being combined with existing obsolete antibiotics in order to make them once again effective in fighting bacterial infections. With the threat of antibiotic resistance growing, companies are likely to look increasingly towards technology such as ARBs for a means of neutralising it.

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cadila Pharmaceuticals Limited, please visit www.cadilapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.